Skip to main content

Advertisement

SpringerLink
Log in

Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany

  • Tätigkeitsberichte
  • Published:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literature

  1. Oliver MB, van der Linden MP, Kuntzel SA, Saad JS, Nahm MH (2013) Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem 288:25976–25985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Robbins JB, Austrian R, Lee CJ et al (1983) Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148:1136–1159

    Article  CAS  PubMed  Google Scholar 

  3. Lee H, Nahm MH, Burton R, Kim KH (2009) Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6 A and 19 A. Clin Vaccine Immunol 16:376–381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jackson LA (2013) Pneumococcal polysaccharide vaccines. In: Vaccines (Hrsg) Plotkin S, Orenstein W, Offit P. Elsevier Saunders, Philadelphia

    Google Scholar 

  5. Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5:83–93

    Article  PubMed  Google Scholar 

  6. van Hoek AJ, Sheppard CL, Andrews NJ et al (2014) Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine 32:4349–4355

    Article  PubMed  Google Scholar 

  7. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378:1962–1973

    Article  PubMed  PubMed Central  Google Scholar 

  8. Klapdor B, Ewig S, Pletz MW et al (2012) Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J 39:1156–1161

    Article  PubMed  Google Scholar 

  9. Kaufman P (1947) Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study. Arch Intern Med (Chic) 79:518–531

    Article  CAS  Google Scholar 

  10. Klugman KP (2013) Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Vaccines (Hrsg) Plotkin S, Orenstein W, Offit P. Elsevier Saunders, Philadelphia

    Google Scholar 

  11. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL (2012) The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 11:841–855

    Article  CAS  PubMed  Google Scholar 

  12. Robert Koch Institut (1998) Ständige Impfkommission (STIKO): Impfempfehlungen der Ständigen Impfkommission (STIKO). Robert Koch Institut, Berlin, S 101–114

    Google Scholar 

  13. Ständige Impfkommission (STIKO) (2009) Pneumokokken-Polysaccharid-Impfung - Anpassung der Empfehlung und Begründung. Epid Bull S 337–338

    Google Scholar 

  14. Ständige Impfkommission (2006) Begründung der STIKO-Empfehlungen zur Impfung gegen Pneumokokken und Meningokokken vom Juli. Ständige Impfkommission (STIKO), Bd. 2006. S 255–260

    Google Scholar 

  15. Poethko-Muller C, Schmitz R (2013) Impfstatus von Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:845–857

    Article  CAS  PubMed  Google Scholar 

  16. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease (IPD) among children and adults in Germany. PLOS ONE 10:e0131494

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Harboe ZB, Dalby T, Weinberger DM et al (2014) Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 59:1066–1073

    Article  CAS  PubMed  Google Scholar 

  18. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV (2014) Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 58:6484–6489

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Garcia Gabarrot G, Lopez Vega M, Giffoni PG et al (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLOS ONE 9:e112337

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Andrews NJ, Waight PA, Burbidge P et al (2014) Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 14:839–846

    Article  CAS  PubMed  Google Scholar 

  21. Andrews NJ, Waight PA, George RC, Slack MP, Miller E (2012) Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 30:6802–6808

    Article  PubMed  Google Scholar 

  22. Bonten MJ, Huijts SM, Bolkenbaas M et al (2015) Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med 372:1114–1125

    Article  CAS  PubMed  Google Scholar 

  23. Bonten MJ, Huijts SM, Bolkenbaas M et al (2015) Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. Supplementary appendix. N Engl J Med 372:1114–1125. doi:10.056/NEJMoa1408544

    Article  CAS  PubMed  Google Scholar 

  24. Choi EH, Zhang F, Lu YJ, Malley R (2015) Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Clin Vaccine Immunol 23:162–167

    Article  PubMed  CAS  Google Scholar 

  25. Jackson LA, Gurtman A, van Cleeff M et al (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 31:3577–3584

    Article  CAS  PubMed  Google Scholar 

  26. Musher DM, Manof SB, Liss C et al (2010) Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 201:516–524

    Article  CAS  PubMed  Google Scholar 

  27. Musher DM, Manoff SB, McFetridge RD et al (2011) Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 7:919–928

    Article  CAS  PubMed  Google Scholar 

  28. Simonsen V, Brandao AP, Brandileone MC et al (2005) Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly. Braz J Med Biol Res 38:251–260

    Article  CAS  PubMed  Google Scholar 

  29. The Nordic Cochrane Centre, The Cochrane Collaboration: Review Manager (RevMan). Copenhagen2014.

  30. Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394

    Article  PubMed  Google Scholar 

  31. Sinclair A, Xie X, Teltscher M, Dendukuri N (2013) Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 51:2303–2310

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pletz MW, von Baum H, van der Linden M et al (2012) The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. Pneumologie 66:470–475

    Article  CAS  PubMed  Google Scholar 

  33. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E (2013) The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Eur J Clin Microbiol Infect Dis 32:305–316

    Article  CAS  PubMed  Google Scholar 

  34. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T (2014) The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 33:1065–1079

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Palmu AA, Saukkoriipi A, Snellman M et al (2014) Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study. Scand J Infect Dis 46:250–259

    Article  PubMed  Google Scholar 

  36. Moberley S, Holden J, Tatham DP, Andrews RM (2013) Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 1:Cd000422

    Google Scholar 

  37. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 6:e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  38. Alfageme I, Vazquez R, Reyes N et al (2006) Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61:189–195

    Article  CAS  PubMed  Google Scholar 

  39. Maruyama T, Taguchi O, Niederman MS et al (2010) Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 340:c1004

    Article  PubMed  PubMed Central  Google Scholar 

  40. Örtqvist A, Hedlund J, Burman LA et al (1998) Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351:399–403

    Article  PubMed  Google Scholar 

  41. Honkanen PO, Keistinen T, Miettinen L et al (1999) Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17:2493–2500

    Article  CAS  PubMed  Google Scholar 

  42. Hechter RC, Chao C, Jacobsen SJ et al (2012) Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Vaccine 30:5625–5630

    Article  CAS  PubMed  Google Scholar 

  43. Jackson LA, Neuzil KM, Yu O et al (2003) Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348:1747–1755

    Article  CAS  PubMed  Google Scholar 

  44. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T et al (2014) Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged 〉/= 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 58:909–917

    Article  CAS  PubMed  Google Scholar 

  45. Tsai YH, Hsieh MJ, Chang CJ et al (2015) The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old-Taiwan's PPV vaccination program. Vaccine 33:2897–2902

    Article  CAS  PubMed  Google Scholar 

  46. Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al (2006) Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 43:860–868

    Article  CAS  PubMed  Google Scholar 

  47. Dominguez A, Salleras L, Fedson DS et al (2005) Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 40:1250–1257

    Article  PubMed  Google Scholar 

  48. Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD (2015) Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged 〉/=65 years: a retrospective case-control study. Clin Infect Dis 60:1472–1480

    PubMed  Google Scholar 

  49. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al (2009) Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 27:1504–1510

    Article  CAS  PubMed  Google Scholar 

  50. Gutierrez Rodriguez MA, Ordobas GMA, Garcia-Comas L et al (2014) Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011. Euro Surveill 19:20922

    Article  CAS  PubMed  Google Scholar 

  51. Rudnick W, Liu Z, Shigayeva A et al (2013) Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine 31:5863–5871

    Article  PubMed  Google Scholar 

  52. Wright LB, Hughes GJ, Chapman KE, Gorton R, Wilson D (2013) Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006–July 2012. Trials Vaccinol 2:45–48

    Article  CAS  Google Scholar 

  53. Wiemken TL, Carrico RM, Klein SL et al (2014) The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 32:2198–2203

    Article  CAS  PubMed  Google Scholar 

  54. Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M (1989) Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect 19:127–134

    Article  CAS  PubMed  Google Scholar 

  55. Leinonen M, Syrjälä H, Jalonen E, Kujala P, Herva E (1990) Demonstration of pneumolysin antibodies in circulating immune complexes—a new diagnostic method for pneumococcal pneumonia. Serodiagn Immunother Infect Dis 4:451–458

    Article  Google Scholar 

  56. Broome CV, Facklam RR, Fraser DW (1980) Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 303:549–552

    Article  CAS  PubMed  Google Scholar 

  57. Higgins JP, Altman DG, Gotzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials Bd. 5928.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Wells GA, Shea B, O'Connell D et al (2015) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Zugegriffen: 10. Juli 2015

    Google Scholar 

  59. Fedson DS, Liss C (2004) Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22:927–946

    Article  CAS  PubMed  Google Scholar 

  60. Dransfield MT, Harnden S, Burton RL et al (2012) Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 55:e35–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Huss A, Scott P, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180:48–58

    Article  PubMed  PubMed Central  Google Scholar 

  62. Andrews R, Moberley SA (2009) The controversy over the efficacy of pneumococcal vaccine. CMAJ 180:18–19

    Article  PubMed  PubMed Central  Google Scholar 

  63. Scott P, Huss A, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal polysaccharide vaccine. CMAJ 180(5):1134–1135

    Article  PubMed  PubMed Central  Google Scholar 

  64. Scott JA, Hall AJ, Leinonen M (2000) Validation of immune-complex enzyme immunoassays for diagnosis of pneumococcal pneumonia among adults in Kenya. Clin Diagn Lab Immunol 7:64–67

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Jalonen E, Taira S, Paton JC, Kerttula Y, Suomalainen P, Leinonen M (1990) Pneumolysin, produced in Bacillus subtilis as antigen in enzyme immunoassay for etiological diagnosis of pneumococcal pneumonia. Serodiagn Immunother Infect Dis 4:459–468

    Article  Google Scholar 

  66. Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE (2001) Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis 32:534–538

    Article  CAS  PubMed  Google Scholar 

  67. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW (2016) Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk - A systematic review and Meta-analysis. PLOS ONE 11:e0146338

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  68. Kraicer-Melamed H, O'Donnell S, Quach C (2016) The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine 34:1540–1550

    Article  CAS  PubMed  Google Scholar 

  69. Christenson B, Hedlund J, Lundbergh P, Ortqvist A (2004) Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 23:363–368

    Article  CAS  PubMed  Google Scholar 

  70. Hak E, Grobbee DE, Sanders EA et al (2008) Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 66:378–383

    CAS  PubMed  Google Scholar 

  71. Pride MW, Huijts SM, Wu K et al (2012) Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 19:1131–1141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Austrian R, Douglas RM, Schiffman G et al (1976) Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 89:184–194

    CAS  PubMed  Google Scholar 

  73. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR (1977) Protective efficacy of pneumococcal polysaccharide vaccines. Jama 238:2613–2616

    Article  CAS  PubMed  Google Scholar 

  74. MacPherson G, Austyn J (2012) Exploring Immunology – Concepts and Evidence. Wiley-Blackwell, Weinheim

    Google Scholar 

  75. Benfield T, Skovgaard M, Schonheyder HC et al (2013) Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccines. PLOS ONE 8:e72743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Rodrigo C, Bewick T, Sheppard C et al (2015) Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45:1632–1641

    Article  PubMed  Google Scholar 

  77. Pilishvili T, Lexau C, Farley MM et al (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201:32–41

    Article  PubMed  Google Scholar 

  78. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ (2010) Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. Bmc Infect Dis 10:90

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  79. Grilli G, Fuiano L, Biasio LR et al (1997) Simultaneous influenza and pneumococcal vaccination in elderly individuals. Eur J Epidemiol 13:287–291

    Article  CAS  PubMed  Google Scholar 

  80. Honkanen PO, Keistinen T, Kivela SL (1996) Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 156:205–208

    Article  CAS  PubMed  Google Scholar 

  81. D'Alessandro D, Ciriminna S, Rossini A, Bossa MC, Fara GM (2004) Requests of medical examinations after pneumococcal & influenza vaccination in the elderly. Indian J Med Res 119(Suppl):108–114

    PubMed  Google Scholar 

  82. Frenck RW Jr., Gurtman A, Rubino J et al (2012) Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 19:1296–1303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Schwarz TF, Flamaing J, Rumke HC et al (2011) A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged 〉/=65 years. Vaccine 29:5195–5202

    Article  CAS  PubMed  Google Scholar 

  84. Greenberg RN, Gurtman A, Frenck RW et al (2014) Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 32:2364–2374

    Article  CAS  PubMed  Google Scholar 

  85. Jackson LA, Gurtman A, Rice K et al (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31:3585–3593

    Article  CAS  PubMed  Google Scholar 

  86. Juergens C, De Villiers PJT, Moodley K et al (2014) Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial. Hum Vaccines Immunother 10:1343–1353

    Article  CAS  Google Scholar 

  87. D'Heilly S, Bauman WL, Nichol KL (2002) Safety and acceptability of pneumococcal vaccinations administered in nontraditional settings. Am J Infect Control 30:261–268

    Article  PubMed  Google Scholar 

  88. Hammitt LL, Bulkow LR, Singleton RJ et al (2011) Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 29:2287–2295

    Article  CAS  PubMed  Google Scholar 

  89. Jackson LA, Benson P, Sneller VP et al (1999) Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281:243–248

    Article  CAS  PubMed  Google Scholar 

  90. Jackson LA, Gurtman A, van Cleeff M et al (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594–3602

    Article  CAS  PubMed  Google Scholar 

  91. Jackson LA, Nelson JC, Whitney CG et al (2006) Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 24:151–156

    Article  CAS  PubMed  Google Scholar 

  92. Manoff SB, Liss C, Caulfield MJ et al (2010) Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 〉 or = years. J Infect Dis 201:525–533

    Article  CAS  PubMed  Google Scholar 

  93. Ohshima N, Nagai H, Matsui H et al (2014) Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine 32:1181–1186

    Article  CAS  PubMed  Google Scholar 

  94. Shih A, Quinley J, Lee TK, Messina CR (2002) Assessing pneumococcal revaccination safety among New York State Medicare beneficiaries. Public Health Rep 117:164–173

    Article  PubMed  PubMed Central  Google Scholar 

  95. Snow R, Babish JD, McBean AM (1995) Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? Public Health Rep 110:720–725

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Törling J, Hedlund J, Konradsen HB, Ortqvist A (2003) Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 22:96–103

    Article  PubMed  CAS  Google Scholar 

  97. Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC (2005) Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 40:1730–1735

    Article  CAS  PubMed  Google Scholar 

  98. Baxendale HE, Johnson M, Keating SM et al (2010) Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 28:6915–6922

    Article  CAS  PubMed  Google Scholar 

  99. Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D (2010) The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 28:4763–4770

    Article  CAS  PubMed  Google Scholar 

  100. Clutterbuck EA, Lazarus R, Yu LM et al (2012) Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 205:1408–1416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Capolunghi F, Cascioli S, Giorda E et al (2008) CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 180:800–808

    Article  CAS  PubMed  Google Scholar 

  102. Khaskhely N, Mosakowski J, Thompson RS, Khuder S, Smithson SL, Westerink MA (2012) Phenotypic analysis of pneumococcal polysaccharide-specific B cells. J Immunol 188:2455–2463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Kruetzmann S, Rosado MM, Weber H et al (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Moens L, Wuyts M, Meyts I, De Boeck K, Bossuyt X (2008) Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol 181:5306–5312

    Article  CAS  PubMed  Google Scholar 

  105. Rosado MM, Gesualdo F, Marcellini V et al (2013) Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol 43:2659–2670

    Article  CAS  PubMed  Google Scholar 

  106. Taillardet M, Haffar G, Mondiere P et al (2009) The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 114:4432–4440

    Article  CAS  PubMed  Google Scholar 

  107. Takizawa M, Sugane K, Agematsu K (2006) Role of tonsillar IgD+CD27+ memory B cells in humoral immunity against pneumococcal infection. Hum Immunol 67:966–975

    Article  CAS  PubMed  Google Scholar 

  108. Weller S, Braun MC, Tan BK et al (2004) Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104:3647–3654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Powers DC, Anderson EL, Lottenbach K, Mink CM (1996) Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 173:1014–1018

    Article  CAS  PubMed  Google Scholar 

  110. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K (2005) Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 175:3262–3267

    Article  CAS  PubMed  Google Scholar 

  111. Tangye SG, Good KL (2007) Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 179:13–19

    Article  CAS  PubMed  Google Scholar 

  112. Leggat DJ, Thompson RS, Khaskhely NM, Iyer AS, Westerink MA (2013) The immune response to pneumococcal polysaccharides 14 and 23 F among elderly individuals consists predominantly of switched memory B cells. J Infect Dis 208:101–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Hussain M, Melegaro A, Pebody RG et al (2005) A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 133:891–898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG (2004) Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190:1203–1211

    Article  PubMed  Google Scholar 

  115. Choi YH, Jit M, Flasche S, Gay N, Miller E (2012) Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PLOS ONE 7:e39927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Reinert RR, Haupts S, van der Linden M et al (2005) Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect (11):985–991

    Article  Google Scholar 

  117. von Kries R, Toschke M, Siedler A, Reinert RR (2004) Population-based Nationwide Study on Invasive Pneumococcal Infections among Children in Germany (1997 - 2003). :130

    Google Scholar 

  118. van Hoek AJ, Andrews N, Waight PA, George R, Miller E (2012) Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLOS ONE 7:e39150

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  119. Aidelsburger P, Grabein K, Bohm K et al (2014) Cost-effectiveness of childhood rotavirus vaccination in Germany. Vaccine 32:1964–1974

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunization Unit, Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

    G. Falkenhorst, C. Remschmidt, T. Harder, O. Wichmann & S. Glodny

  2. Department of General Practice, University Medical Center Göttingen, Göttingen, Germany

    E. Hummers-Pradier

  3. Medical Practice, Ditzingen, Germany

    T. Ledig

  4. Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany

    C. Bogdan

Authors
  1. G. Falkenhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Remschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Harder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. Wichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Glodny
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Hummers-Pradier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Ledig
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Bogdan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falkenhorst, G., Remschmidt, C., Harder, T. et al. Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsbl 59, 1623–1657 (2016). https://doi.org/10.1007/s00103-016-2466-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00103-016-2466-9

Search

Navigation